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Abstract
Background: D-glucuronyl C5-epimerase (GLCE) is one of the key enzymes in the biosynthesis of heparansulfate
proteoglycans. Down-regulation of GLCE expression in human breast tumours suggests a possible involvement of
the gene in carcinogenesis. In this study, an effect of GLCE ectopic expression on cell proliferation and viability of
breast carcinoma cells MCF7 in vitro and its potential molecular mechanisms were investigated.
Results: D-glucuronyl C5-epimerase expression was significantly decreased in MCF7 cells compared to normal
human breast tissue. Re-expression of GLCE inhibited proliferative activity of MCF7 cells according to CyQUANT NF
Cell Proliferation Assay, while it did not affect their viability in Colony Formation Test. According to Cancer
PathFinder RT Profiler PCR Array, antiproliferative effect of GLCE in vitro could be related to the enhanced
expression of tumour suppressor genes р53 (+3.3 fold), E2F1 (+3.00 fold), BRCA1 (+3.5 fold), SYK (+8.1 fold) and
apoptosis-related genes BCL2 (+4.2 fold) and NFKB1 (+2.6 fold). Also, GLCE re-expression in MCF7 cells considerably
changed the expression of some genes involved in angiogenesis (IL8, +4.6 fold; IFNB1, +3.9 fold; TNF, +4.6 fold and
TGFB1, -5.7 fold) and invasion/metastasis (SYK, +8.1 fold; NME1, +3.96 fold; S100A4, -4.6 fold).
Conclusions: The ability of D-glucuronyl С5-epimerase to suppress proliferation of breast cancer cells MCF7 through
the attenuated expression of different key genes involved in cell cycle regulation, angiogenesis and metastasis
molecular pathways supports the idea on the involvement of the gene in regulation of breast cancer cell
proliferation.
Background
D-glucuronyl C5-epimerase (GLCE) is one of the key
enzymes responsible for biosynthesis of the carbohydrate
part of heparan sulfate proteoglycans (HSPGs) -
complex protein-carbohydrate molecules localized on
the cell surface and in extracellular matrix (ECM).
HSPGs interact with numerous ligands, including many
growth factors, cytokines, receptors and extracellular
matrix molecules and mediate cell signaling events con-
trolling migration, proliferation and differentiation [1-4].
Abnormal expression or deregulated function of these
proteoglycans crucially affect cell-cell and cell-matrix
interactions and promote different pathologies including
malignant transformation [5,6].
In many cases, the structure of the heparan sulfate
(HS) polysaccharide chains is a major determinant of
HSPGs function [7]. Changes in expression of heparan
sulfates, as well as of enzymes involved in their bio-
synthesis and degradation, contribute to different steps
of tumour progression [8] and study of the heparan sul-
fate biosynthesis system has a critical importance since
its defect affects all HSPGs synthesised by the cell [5].
One of the key enzymes of HS biosynthesis is
D-glucuronyl C5-epimerase that is responsible for epi-
merization of D-glucuronyl residue (D-GlcUA) into
L-iduronyl residue (L-IdoUA) in HS carbohydrate chains
[9]. Up to date, there are not so many data concerning
mammalian D-glucuronyl C5-epimerase and no data on
human GLCE. The gene was cloned from bovine lung
[10], mouse liver [11] and mouse mastocytoma cells
[12]; knockdown of a murine glucuronyl C5-epimerase
gene resulted in neonatal lethality of experimental ani-
mals [13]. It was shown that the gene is involved in the
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embryonic development of Danio rerio [14] and
its expression is regulated via beta-catenin-TCF4
transactivation pathway [15].
Some indirect data also support an importance of
GLCE in cell physiology - a presence of flexible IdoUA
residues in HS is necessary for the interaction of
heparan sulfates with FGF2 and subsequent cell signal-
ing [16] and for the interaction of hepatocyte growth
factor/scatter factor with its signaling receptor MET
[17].
Our previous data on significant down-regulation of
GLCE expression in human breast tumours suggested a
possible involvement of the gene in carcinogenesis
[18,19].
We hypothesized that GLCE expression could be
involved in regulation of breast cancer cell prolifera-
tion through the changed structure/composition of cell
surface heparan sulfates and tumour microenviron-
ment. To test this hypothesis, we ectopically expressed
D-glucuronyl C5-epimerase in MCF7 breast cancer
cells at the physiological level and analyzed a prolifera-
tive activity and viability of the epimerase-expressing
cells as well as possible molecular mechanisms of the
functional effect of GLCE in vitro.
Results
D-glucuronyl C5-epimerase cloning
To study a functional role of D-glucuronyl C5-epimerase
in human breast cancer cells, it was necessary to have
the gene cloned into the specific plasmid vector for the
effective expression in mammalian cells. As a human
D-glucuronyl C5-epimerase has not been cloned, we
amplified a full-length GLCE from the KIAA-00836-
pBluescript plasmid (Kazusa DNA Research Institute,
Japan) containing 5’-truncated epimerase fragment. A
long 59 DNA oligonucleotide was used as a forward pri-
mer to re-build a 5’-missing part of the gene. Amplified
full-length DNA fragment was cloned into episomal vector
рСЕР4 (Invitrogen). Nucleotide sequence of D-glucuronyl
C5-epimerase was verified by sequencing and the obtained
DNA plasmid was designated as epi-pCEP4.
D-glucuronyl C5-epimerase expression in human breast
cancer cells MCF7
Previously, it was shown that D-glucuronyl C5-epimerase
expression is significantly down-regulated in 82-84% of
the human breast tumours [19]. As a first step of the
study, GLCE expression in human breast cancer cells
MCF7 was estimated using multiplex RT-PCR (Fig.1).
According to our results, D-glucuronyl C5-epimerase
expression is significantly decreased in MCF7 cells com-
pared with the normal human breast tissue. Transfec-
tion of the cells with epi-pCEP4 plasmid restored a
GLCE expression almost up to physiological level in epi-
MCF7 clones 3 and 4. Epi-MCF7 clone 1 did not
expressed GLCE in spite of plasmid presence and was
considered as a control as well as MCF7 cells trans-
fected with an empty vector pCEP4 (pCEP4-MCF7
cells).
An influence of D-glucuronyl C5-epimerase on viability
and proliferation of breast carcinoma cells MCF7 in vitro
Viability and proliferation rate of breast cancer cells in
vitro were investigated using Colony Formation Test
and the CyQUANT NF Cell Proliferation Assay (Invitro-
gen) (Fig.2).
It was demonstrated that D-glucuronyl C5-epimerase
ectopic expression did not influence the viability of
breast cancer cells MCF7 in Colony Formation Test -
the number of epi-MCF7 colonies per 10 mm plate was
even higher than those on the plates with MCF7 and
pCEP4-MCF7 cells (Fig.2A). However, a difference in
growth rate of the epi-MCF7 and pCEP4-MCF7 colonies
suggested a different proliferation rate of the cells.
Proliferative activity of the cells stably expressing D-
glucuronyl C5-epimerase (epi-MCF7 clones 3 and 4)
and control MCF7 cells (pCEP4-MCF7 and epi-
MCF7clone 1) was determined using the CyQUANT
NF Cell Proliferation Assay. The assay is based on
measurement of cellular DNA content via fluorescence
dye binding and designed to produce a linear analytical
response from at least 100-20,000 cells per well in
most cell lines in a 96-well microplate. Fluorescence
intensities were measured every 24 hours and plotted
on diagram (Fig.2B). According to this assay,
Figure 1 D-glucuronyl C5 epimerase expression in normal
human breast tissue and breast cancer cells. A - multiplex RT-
PCR with primers for GLCE and GAPDH; B - GLCE expression
referenced to GAPDH (TotalLab Рrogramme, Nonlinear Dynamics,
UK). The data are shown as mean ± S.D.
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D-glucuronyl C5-epimerase re-expression in epi-MCF7
cells (clones 3 and 4) significantly (4-5 fold) sup-
pressed their proliferative activity compared with the
control cells, not expressing epimerase (MCF7, pCEP4-
MCF7 and epi-MCF7 clone 1).
Therefore, re-expression of D-glucuronyl C5-epimerase
in human breast cancer cells MCF7 significantly sup-
pressed proliferative activity of the cells without affect-
ing their viability, suggesting regulatory rather than
suppressing function of the gene.
Molecular mechanisms of antiproliferative effect of
D-glucuronyl C5-epimerase
To reveal possible molecular mechanisms of the anti-
proliferative effect of D-glucuronyl C5-epimerase to
human breast cancer cells in vitro, Cancer PathFinder
RT Profiler PCR Array (SABiosciences) was used. This
system profiles the expression of 84 genes representative
of the six biological pathways involved in carcinogenesis
(cell cycle control, signal transduction, apoptosis and
cell senescence, angiogenesis, adhesion, invasion and
metastasis) (http://www.sabiosciences.com/rt_pcr_pro-
duct/HTML/PAHS-033A.html). The relative expression
levels of each gene in any two samples (experimental
and control) are plotted against each other in the Scat-
ter Plot revealing genes up- and down-regulated in the
experimental sample. In this study, epimerase-expressing
MCF7 cells (clones 3 and 4) were compared with the
control pCEP4-MCF7 cells (Fig.3).
It was shown that expression of 22 genes was either
down- or up-regulated more than 2 fold while the
expression of the remaining 62 genes were unaffected.
To analyze the combination and functional importance
of the influenced genes, we placed all genes with more
than 2-fold expression change in epi-MCF7 cells in one
diagram (Fig.4).
Re-expression of D-glucuronyl C5-epimerase in breast
cancer cells MCF7 influenced the expression of some
cancer-related genes involved mostly in three molecular
pathways:
1. cell cycle control and DNA damage repair (up-
regulation of tumour-suppressing genes р53 (+3.3
fold), BRCA1 (+3.5 fold), SYK (+8.1 fold) and tran-
scription factor E2F1 (+3.00 fold));
2. angiogenesis (changes in the expression of IL8 (+4.6
fold), IFNB1 (+3.9 fold), TNF (+4.6 fold) and TGFB1
(-5.7 fold));
3. invasion and metastasis (up-regulation of metasta-
sis-suppressor genes SYK (+8.1 fold) and NME1 (+3.96
fold) and down-regulation of metastasis associated gene
S100A4 (-4.6 fold)).
Also, up-regulation of apoptosis-related genes BCL2
(+4.2 fold) and NFKB1 (+2.6 fold) was detected.
The obtained data indicated that antimitotic effect of
D-glucuronyl C5-epimerase in human breast cancer cells
in vitro probably is realized mainly via the activation of
tumour suppressor genes р53, BRCA1, SYK and E2F1
and change of a balance of pro- and anti-apoptotic fac-
tors BCL2, NFKB1 and TNF.
Discussion
The primary aim of this study was to investigate a possi-
ble interrelation between D-glucuronyl C5-epimerase
expression and proliferative activity of human breast
cancer cells. The obtained results support the hypothesis
that GLCE re-expression in human breast cancer cells
MCF7 indeed suppresses their proliferation in vitro. It is
not something unexpected - tumour-suppressor function
was shown for another HS-synthesizing enzyme EXT1,
which is responsible for the initial step of heparan sul-
fate (HS) chain elongation [20]. It was shown that epige-
netic inactivation of EXT1, leading to an abrogation of
HS biosynthesis, is common for leukemia and non-mela-
noma skin cancer, and reintroduction of EXT1 into
HS-deficient leukemia cells HL-60 suppressed colony
formation and growth of tumour xenografts [20]. Ext1
mutation in mouse embryonic fibroblasts resulted in
substantially reduced HS chains length, reduced ability
to attach to collagen I and impaired FGF2 signaling that
also could be rescued by reintroduction of Ext1 [21]. In
our target cell line MCF7, EXT1 is actively expressed
Figure 2 Effect of D-glucuronyl C5-epimerase on viability and
proliferation rate of human breast cancer cells. Colony
formation efficiency (A) and proliferative activity (B) of epimerase-
expressing breast cancer cells MCF7. pCEP4-MCF7 - control MCF7
cells transfected with рСЕР4 vector; 1,3,4 - epi-MCF7 clones.
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and HS chains are present in the cells [20] but GLCE
expression is almost abrogated. It suggests a decreased
IdoUA content in heparan sulfate chains that is critically
important for interaction of the HS with growth factors
and appropriate cell signaling [16,17]. The changes in
HS structure could influence, in turn, a gene expression
profile of the cells and various molecular mechanisms
involved in the regulation of cell proliferation.
Thus, our results suggest D-glucuronyl C5-epimerase
as a second candidate tumour-suppressor gene (TSG)
from the HS biosynthetic machinery, whose inactivation
in breast cancer cells MCF7 could contribute to breast
tissue-specific malignant transformation.
To reveal the molecular mechanisms of antiprolifera-
tive effect of D-glucuronyl C5-epimerase in breast cancer
cells MCF7, PathFinder RT Profiler PCR Array was
applied. Analysis of the obtained results showed that
molecular mechanisms of cell cycle control, angiogenesis
and invasion/metastasis were affected in the epimerase-
expressing MCF7 cells.
In our in vitro experimental system, re-expression of
D-glucuronyl C5-epimerase in breast cancer cells MCF7
significantly (3-8 fold) increased expression level of the
breast tumour suppressor genes BRCA1 [22] and SYK
(Spleen Tyrosine Kinase) [23] which are known as
important inhibitors of breast cancer cell growth and
metastasis. Other cancer-related genes influenced by the
ectopic expression of GLCE were transcription factors
p53 and E2F1 that are key molecules of the INK4A-Rb-
E2f and ARF-MDM2-p53 pathways and pivotal regula-
tors of cell proliferation and viability. Recent data reveal
that there is extensive crosstalk between the pathways
and in particular between the transcription factors E2F1
and p53 which cooperate in inhibition of tumourigenesis
by activation of many pro-apoptotic genes and inducing
cell death [24]. From the other side, E2F-containing
Figure 3 Cancer PathFinder RT2 Profiler™ PCR Array analysis of epimerase-expressing breast cancer cells MCF7. The relative expression
levels for each gene in the epimerase-expressing MCF7 cells (Group 1) are plotted against the ones from the control pCEP4-MCF7 cells (Control
Group) in the Scatter Plot. Diagonal shows the same expression in both groups with 2-fold change boundaries. Genes up-regulated in the epi-
MCF7 cells more than 2-fold are marked above the middle lane and down-regulated genes are marked below the lane.
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protein complexes mediate p53-induced growth arrest
and senescence indicating the contradictory role of E2F1
in tumourigenesis that is context dependent and tissue
specific [24].
In this study, the ectopic expression of human D-
glucuronyl C5-epimerase in MCF7 cells increased the
expression of both p53 and E2F1 but the expression
of almost all tested apoptosis-involved genes were
unaffected and viability of the epimerase-expressing
MCF7 cells were even slightly higher that the control
ones (Fig.3). It suggests that GLCE-activated p53 and
E2F1 expression more likely affects molecular path-
ways promoting growth arrest and senescence rather
than apoptotic functions of both p53 and E2F1, like
their potentially crucial regulator SIRT1 [24]. The
hypothesis is also supported by an increased expres-
sion of the anti-apoptotic genes BCL2 [25], TNF and
transcriptional factor NF-kappaB which protects breast
cancer cells from apoptosis [26].
Taken together, these data suggest that up-regulation
of the expression of the tumour-suppressor genes (р53,
BRCA1, SYK) and transcription factor E2F1 could be
responsible for the antimitotic effect of D-glucuronyl
C5-epimerase in human breast cancer cells in vitro.
Another important observation was that ectopic D-
glucuronyl C5-epimerase expression led to significant
change of the expression of genes involved in angiogen-
esis (IL8, IFNB1, TNF) and invasion/metastasis (SYK,
NME1, S100A4, TGFb). Among them, there are both
microenvironment-dependent regulators of tumour
initiation, progression and metastasis like TGFb that has
diverse and often conflicting roles in tumour progres-
sion [27] and tumour- and metastasis-suppressor gene
SYK [23], metastasis suppressor gene NME1 [28] and
metastasis-associated gene S100A4 (MTS1, metastasin)
[29].
Interestingly, all those changes have a clearly anti-
metastatic trend - re-expression of GLCE in breast
Figure 4 Up- and Down-regulated genes in D-glucuronyl C5-epimerase-expressing breast cancer cells MCF7. The relative expression levels
for each gene in epi-MCF7 (Group 1) and pCEP4-MCF7 (Control Group) cells are plotted against each other. Diagonal marks an equal expression
of the gene, bounded region corresponds to 2-fold change of expression.
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cancer cells MCF7 up-regulates the expression of sup-
pressor genes SYK and NME1 and down-regulates the
expression of metastasis marker S1004A and TGFb. It is
not something completely unexpected since the process
of metastasis is dependent on adhesion properties of
cells and their interaction with tumour microenviron-
ment, which are determined in significant extent by the
structure and composition of heparan sulfates at ECM
and cell surface. From the obtained data, we can
hypothesize that the expression of D-glucuronyl C5-
epimerase in breast cancer cells not only inhibits their
proliferation in vitro but could suppress tumour growth
and metastasis in vivo through the influence on cell
microenvironment and tumour angiogenesis, which
could be one of the future perspectives to study.
Conclusions
In summary, the obtained results showed that D-
glucuronyl C5-epimerase significantly suppress prolif-
erative activity of breast cancer cells in vitro through
the activation of tumour suppressor genes р53,
BRCA1, SYK and E2F1 and change of a balance of
pro- and apoptotic factors BCL2, NFKB1 and TNF.
The ability of D-glucuronyl C5-epimerase to affect
simultaneously several different key genes of the cell
cycle regulation (р53, E2F1, BRCA1), angiogenesis (IL8,
IFNB1, TNF, TGFB1) and metastasis (SYK, NME1,
S100A4, TGFb) supports the idea on the involvement of
the gene in regulation of breast cancer cell proliferation.
Methods
Cell lines and culture conditions
Human breast cancer cell line MCF7 was obtained from
Karolinska Institute (Stockholm, Sweden). Cells were
maintained in IMDM medium supplemented with 2
mM L-glutamine, 100 units penicillin 100 μg/ml strep-
tomycin and 10% (v/v) fetal bovine serum at 37°C in a
humidified 5% CO2. For analysis cells were harvested by
standard protocol using trypsin/EDTA (Sigma, USA).
Human D-glucuronyl C5-epimerase cloning
Human D-glucuronyl C5-epimerase (GLCE)
(NM_015554) was cloned into episomal vector pCEP4
(Invitrogen, USA). Full-length sequence of epimerase
cDNA was amplified by PCR with Pfu-DNA-polymerase
(Stratagene) and epi-oligo-F 5′-CTAAGATCTAGA-
TATGCGTTGCTTGGCAGCTCGGGTCAACTATAA-
GACTTTGATTATTA-3′ and epi-R 5′-TACAGCGG
CCGCTGAAGTGCAGTTTTGGT-3′ primers from
KIAA0836 clone (AB_020643) coding 5′-truncated
sequence of the GLCE (Kazusa DNA Research Institute,
Japan). Amplified full-length fragment was cloned into
pCEP4 vector and obtained plasmid was defined as epi-
pCEP4. GLCE sequence was verified by sequencing
(Dye Terminator Cycle sequencing Kit and ABI PRISM
3700 genetic analyzer).
Transfection and selection of stable cell clones
To obtain stable cell clones expressing D-glucuronyl C5-
epimerase, MCF7 cells were transfected with epi-pCEP4
or pCEP4 plasmid DNA (0.5 μg DNA/well) using Lipo-
fectamine-ReagentPlus combination (Invitrogen, USA)
according to the manufacturer’s protocol. Stable cell
clones were selected for 2-3 weeks in IMDM medium
containing 200 μg/ml Hygromycin (Sigma, USA).
Colony formation assay
pCEP4- or epi-pCEP4-transfected MCF7 cells were
stripped 24-48 h after transfection and plated on 100
mm cell culture dishes at 500-1000 cells per plate. After
selection by 200 μg/ml Hygromycin for 2 weeks,
giemsa-stained colonies were photographed and counted
by Quantitione software, Version 4.4.0 (Bio-Rad, USA).
RT-PCR analysis of GLCE expression
Total RNA was isolated from the cells using PureLink
Total RNA Purification System (Invitrogen, Carlsbad,
CA) according to manufacturer’s protocol. Synthesis of
cDNA was performed from 1 μg of total mRNA using
First Strand cDNA Synthesis kit (Fermentas, Hanover,
MD) according to manufacturer’s instruction. Multiplex
PCR was performed in 20 μl volume (200 ng cDNA, 2
μl 10*PCR buffer 10 mM Tris-HCl, 1,5 mM MgCl2, 50
mM KCl, pH 8,3, 5 pmole of each primer, 0,2 mmole of
each dNTP and 1 unit Taq-Polymerase) in Tercik PCR
machine (DNA Technology, Russia). PCR conditions:
95°C 10 min, 95°C 15 s, 59°C 15 s and 72°C 1 min with
final elongation at 72°C 10 min; 32 cycles for GAPDH
and 20 cycles for GLCE. Following primers were used:
GLCE-F, 5′-AAGGGAGACGAGAGGGGAACGAA-3′;
GLCE-R, 5′GCCACCTTTCTCATCCTGGTTC-3′;
GAPDH-F, 5′-GGGCGCCTGGTCACAA-3′; GAPDH-R,
5′-AACATGGGGGCATCAGCAGA-3′.
Products of amplification were analyzed by electro-
phoresis in 1.2% agarose gel and visualized using “DNA
Analyzer” system (Moscow, Russia). GLCE expression
level was estimated as a ratio of GLCE DNA fragment
intensity to GAPDH DNA fragment intensity (TotalLab
Рrogramme, Nonlinear Dynamics, UK).
Cell proliferation assay in vitro
Cell proliferation rate was estimated using the CY
QUANT NF Cell Proliferation Assay (Invitrogen, USA)
according to manufacturer’s instruction. Cells were pla-
ted at densities 100-500 cells/well to 8-12 wells in a
96-well microplate. DNA content in the wells was mea-
sured every 24 hours - the medium was removed and
50 μl fluorescent dye was added followed by incubation
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for 30 min at 37°C. Fluorescent intensity of each sample
was measured at 485/530 nm with Fluorescence Micro-
plate Reader (SPECTRA max, “Molecular Devices”, UK).
Cancer-related genes expression profiling
To identify possible molecular mechanisms of antiproli-
ferative effect of GLCE, Cancer PathFinder RT2 Profiler™
PCR Array (SABioscience, Frederick, MD) was used.
Total RNA was isolated using RNAqueous Micro Kit
(Applied Biosystems, Foster City, CA) according to
manufacturer’s protocol. RNA concentration was mea-
sured with Quant-iT Assay Kit and Qubit instrument
(Invitrogen, USA), RNA quality was evaluated by elec-
trophoresis. cDNA was synthesized from 1-2 μg total
RNA using First Strand cDNA Synthesis kit (Fermentas,
Hanover, MD). Real-time PCR was performed with
SYBR Green PCR Master Mix (Fermentas, Hanover,
MD) and iCycler iQ5 Multicolor Detection System (Bio-
Rad, USA) according to manufacturer’s instructions.
Obtained data were analyzed with Excel-based PCR
Array Data Analysis Software (SABioscience, Frederick,
MD).
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